HC Wainwright Analysts Give Omeros (OMER) a $30.00 Price Target
A number of other equities research analysts have also weighed in on OMER. Maxim Group set a $24.00 target price on shares of Omeros and gave the company a buy rating in a research note on Monday. Zacks Investment Research lowered shares of Omeros from a buy rating to a hold rating in a research note on Wednesday, October 25th. Wedbush reiterated an outperform rating and set a $47.00 target price on shares of Omeros in a research note on Tuesday, November 28th. Finally, Cowen lowered shares of Omeros from an outperform rating to a market perform rating in a research note on Thursday, November 2nd. Five research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $34.14.
Omeros (NASDAQ OMER) traded up $0.26 during mid-day trading on Tuesday, reaching $17.44. The company had a trading volume of 649,900 shares, compared to its average volume of 820,880. The company has a market cap of $810.30, a PE ratio of -13.52 and a beta of 3.56. Omeros has a fifty-two week low of $8.71 and a fifty-two week high of $27.09. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74.
Large investors have recently bought and sold shares of the company. First Interstate Bank purchased a new stake in shares of Omeros in the 3rd quarter worth $108,000. Legal & General Group Plc increased its stake in shares of Omeros by 7.8% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 751 shares in the last quarter. Hanseatic Management Services Inc. increased its stake in shares of Omeros by 10,919.6% in the 3rd quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 10,592 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Omeros in the 3rd quarter worth $256,000. Finally, SG Americas Securities LLC increased its stake in shares of Omeros by 138.9% in the 3rd quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock worth $263,000 after purchasing an additional 7,067 shares in the last quarter. Hedge funds and other institutional investors own 49.85% of the company’s stock.
WARNING: “HC Wainwright Analysts Give Omeros (OMER) a $30.00 Price Target” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/hc-wainwright-analysts-give-omeros-omer-a-30-00-price-target/1822047.html.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.